Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous versus intermittent beta-lactam dosing in ICU sepsis
PACTR202009811610400Not yet recruiting
- Sponsor
- Applied for and awaiting approval
- Start
- Sep 2020
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of amoxicillin + clavulanate, piperacillin + tazobactam, meropenem and imipenem in sepsis (2 arms), sponsored by Applied for and awaiting approval. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
amoxicillin + clavulanatepiperacillin + tazobactammeropenemimipenem
03
Conditions
sepsis
Beyond the preview
Go deeper on PACTR202009811610400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202009811610400.